Fludarabine phosphate therapy of non-Hodgkin's lymphoma.
Fludara I.V. (fludarabine phosphate) was tested by the Eastern Cooperative Oncology Group in non-Hodgkin's lymphoma patients who failed or relapsed after prior chemotherapy and radiation. Fifty-seven patients with low- or intermediate-grade (working formulation) lymphoma were treated with 18 mg/m2 daily for 5 days every 28 days. Preliminary data analysis shows an overall response (complete response [CR] plus partial response [PR]) rate of 28%, consisting of 18% CR and 27% PR in patients with low-grade histologies and 11% CR and 6% PR in patients with intermediate-grade histologies. Toxicity was mild and mainly included moderate myelosuppression. A 9% incidence of reversible neurologic side effects was seen. Based on this activity in previously treated patients, combination studies with Fludara I.V. in untreated patients are planned.
Hochster
H
H
Division of Medical Oncology, Kaplan Cancer Center, New York University Medical Center, NY 10016.
Cassileth
P
P
D000328:Adult; D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009422:Nervous System Diseases / Q000139:chemically induced; D012074:Remission Induction; D015996:Survival Rate; D001084:Vidarabine Phosphate / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use
D000964:Antimetabolites, Antineoplastic; D001084:Vidarabine Phosphate; C042382:fludarabine phosphate